The LifeCycle Project-EU Child Cohort Network : a federated analysis infrastructure and harmonized data of more than 250,000 children and parents

Early life is an important window of opportunity to improve health across the full lifecycle. An accumulating body of evidence suggests that exposure to adverse stressors during early life leads to developmental adaptations, which subsequently affect disease risk in later life. Also, geographical, socio-economic, and ethnic differences are related to health inequalities from early life onwards. To address these important public health challenges, many European pregnancy and childhood cohorts have been established over the last 30 years. The enormous wealth of data of these cohorts has led to important new biological insights and important impact for health from early life onwards. The impact of these cohorts and their data could be further increased by combining data from different cohorts. Combining data will lead to the possibility of identifying smaller effect estimates, and the opportunity to better identify risk groups and risk factors leading to disease across the lifecycle across countries. Also, it enables research on better causal understanding and modelling of life course health trajectories. The EU Child Cohort Network, established by the Horizon2020-funded LifeCycle Project, brings together nineteen pregnancy and childhood cohorts, together including more than 250,000 children and their parents. A large set of variables has been harmonised and standardized across these cohorts. The harmonized data are kept within each institution and can be accessed by external researchers through a shared federated data analysis platform using the R-based platform DataSHIELD, which takes relevant national and international data regulations into account. The EU Child Cohort Network has an open character. All protocols for data harmonization and setting up the data analysis platform are available online. The EU Child Cohort Network creates great opportunities for researchers to use data from different cohorts, during and beyond the LifeCycle Project duration. It also provides a novel model for collaborative research in large research infrastructures with individual-level data. The LifeCycle Project will translate results from research using the EU Child Cohort Network into recommendations for targeted prevention strategies to improve health trajectories for current and future generations by optimizing their earliest phases of life.Peer reviewe

Neoplastic lymphangiosis of the upper aerodigestive tract simulating field cancerization: histopathological analysis, surgical limits and literature review

Neoplastic lymphangiosis is defined as extensive embolic spread of cancer cells in the lymphatic vessels often without any evidence of a mass. Instead, field cancerization is defined by the presence of multifocal neoplastic lesions in a mucosal field previously exposed to mutagenic factors. In this case report, this oncological entity was suggested by the wide extent and multifocality of the disease and by the patient's exposure to risk factors. Instead, the pathological slides revealed the integrity of the mucosa and the presence of widespread embolic metastasis to lymphatic vessels. Thus, the diagnosis was changed to neoplastic lymphangiosis. This clinical presentation is a negative prognostic factor, and surgical treatment is ineffective because of the impossibility to obtain adequate free margins. The present case underlines the poor prognosis of such locally advanced cancer and the importance of recognizing it early so that the treatment approach can be adapted

Respuesta frente a la pandemia por SARS CoV-2 en Córdoba: detección de anticuerpos neutralizantes individuos recuperados en el territorio de la Provincia. INFORME: Documento Consenso NT – Cordoba 1-7-2020

El Instituto de Virología “Dr. J. M. Vanella” (InViV), dependiente de esta Facultad de Ciencias Médicas de la Universidad Nacional de Córdoba, informa los resultados preliminares de la detección de anticuerpos neutralizantes anti-SARS CoV-2 en Córdoba, en un grupo de individuos recuperados de la infección. La información que se muestra en este documento forma parte de los datos obtenidos en el trabajo conjunto entre el Instituto de Virología “Dr. J. M. Vanella” (InViV) de la Facultad de Ciencias Médicas de la Universidad Nacional de Córdoba, el Ministerio de Salud de la Provincia de Córdoba, el Laboratorio Central de la Provincia de Córdoba, el Hospital Rawson de Córdoba y el Centro de Plasmaféresis provincial, quienes se encuentran trabajando en forma conjunta y coordinada para dar respuesta a las necesidades diagnósticas en el contexto de la actual pandemia.Fil: Pizzi; Rogelio. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas. Instituto de Virología Dr. J. M. Vanella; Argentina.Fil: Gallego; Sandra. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas; Argentina.Fil: Blanco, Sebastián. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas; Argentina.Fil: Díaz, Adrián. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas; Argentina.Fil: Spinsanti, Lorena. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas; Argentina.Fil: Konigheim, Brenda. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas; Argentina.Fil: Aguilar, Javier. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas; Argentina.Fil: Ré, Viviana. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas; Argentina.Fil: Nates, Silvia. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas; Argentina.Fil: Cardozo, Diego. Gobierno de la Provincia de Córdoba. Ministerio de Salud; Argentina.Fil: Barbás, María Gabriela. Gobierno de la Provincia de Córdoba. Ministerio de Salud. Secretaría de Prevención y Promoción de la Salud; Argentina.Fil: López, Laura. Gobierno de la Provincia de Córdoba. Ministerio de Salud. Secretaría de Prevención y Promoción de la Salud; Argentina.Fil: González, Patricia. Gobierno de la Provincia de Córdoba. Ministerio de Salud. Secretaría de Prevención y Promoción de la Salud; Argentina.Fil: Savoretti, Magalí. Gobierno de la Provincia de Córdoba. Ministerio de Salud. Secretaría de Prevención y Promoción de la Salud; Argentina.Fil: Altamirano, Natalia. Gobierno de la Provincia de Córdoba. Ministerio de Salud. Laboratorio Central; Argentina.Fil: Almada, Soledad. Gobierno de la Provincia de Córdoba. Ministerio de Salud. Laboratorio Central; Argentina.Fil: Castro, Gonzalo. Gobierno de la Provincia de Córdoba. Ministerio de Salud. Laboratorio Central; Argentina.Fil: Sicilia, Paola E. Gobierno de la Provincia de Córdoba. Ministerio de Salud. Laboratorio Central; Argentina.Fil: Gignard, Susana. Gobierno de la Provincia de Córdoba. Ministerio de Salud. Laboratorio Central; Argentina.Fil: Borda, Mariel. Gobierno de la Provincia de Córdoba. Ministerio de Salud. Laboratorio Central; Argentina.Fil: Díaz, Miguel. Hospital Rawson; Argentina.Fil: Collino, César. Hospital Rawson; Argentina.Fil: Visintín, Gustavo. Gobierno de la Provincia de Córdoba. Ministerio de Salud. Centro de Plasmaféresis de la Provincia de Córdoba; Argentina.Fil: Espil, Lorena. Gobierno de la Provincia de Córdoba. Ministerio de Salud. Centro de Plasmaféresis de la Provincia de Córdoba; Argentina

Diccionario de acontecimientos de derechas en el siglo XXI en América Latina

Este libro se origina fruto del diálogo y la construcción mancomunada del conocimiento en el Centro de Estudios Comparados de la Facultad de Ciencia Política y Relaciones Internacionales de la Universidad Nacional de Rosario y en el marco de la integración de preocupaciones e intereses de distintos proyectos de investigación radicados en esta universidad y en el CONICET. Esto explica la heterogeneidad que presentan los/as distintos autores/as de las entradas, desde académicos de trayectoria, investigadores en proceso de formación, hasta estudiantes avanzados. Diccionario de acontecimientos de derechas en el siglo XXI en América Latina es una obra de referencia para la reflexión profunda, articulada y sesuda de los itinerarios, derroteros y fisonomía que adquieren las derechas políticas en la región, en un siglo de vértigo, cambio y vorágine. Por ello, es una obra recomendada para quienes busquen auscultar la complejidad de la política regional en el siglo XXI; reconocer las facetas y lindes que adquieren las derechas en cada uno de los países cuando se tornan visibles en el espacio público político; y, finalmente, advertir las continuidades y rupturas de la historia política contemporánea de América Latina a la luz de sus pliegues y acontecimientos más destacados.Fil: Iglesias, Esteban. Universidad Nacional de Rosario. Facultad de Ciencia Política y Relaciones Internacionales; Argentina

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial

Background The best treatment option for patients with type 2 diabetes in whom treatment with metformin alone fails to achieve adequate glycaemic control is debated. We aimed to compare the long-term effects of pioglitazone versus sulfonylureas, given in addition to metformin, on cardiovascular events in patients with type 2 diabetes. Methods TOSCA.IT was a multicentre, randomised, pragmatic clinical trial, in which patients aged 50\ue2\u80\u9375 years with type 2 diabetes inadequately controlled with metformin monotherapy (2\ue2\u80\u933 g per day) were recruited from 57 diabetes clinics in Italy. Patients were randomly assigned (1:1), by permuted blocks randomisation (block size 10), stratified by site and previous cardiovascular events, to add-on pioglitazone (15\ue2\u80\u9345 mg) or a sulfonylurea (5\ue2\u80\u9315 mg glibenclamide, 2\ue2\u80\u936 mg glimepiride, or 30\ue2\u80\u93120 mg gliclazide, in accordance with local practice). The trial was unblinded, but event adjudicators were unaware of treatment assignment. The primary outcome, assessed with a Cox proportional-hazards model, was a composite of first occurrence of all-cause death, non-fatal myocardial infarction, non-fatal stroke, or urgent coronary revascularisation, assessed in the modified intention-to-treat population (all randomly assigned participants with baseline data available and without any protocol violations in relation to inclusion or exclusion criteria). This study is registered with ClinicalTrials.gov, number NCT00700856. Findings Between Sept 18, 2008, and Jan 15, 2014, 3028 patients were randomly assigned and included in the analyses. 1535 were assigned to pioglitazone and 1493 to sulfonylureas (glibenclamide 24 [2%], glimepiride 723 [48%], gliclazide 745 [50%]). At baseline, 335 (11%) participants had a previous cardiovascular event. The study was stopped early on the basis of a futility analysis after a median follow-up of 57\uc2\ub73 months. The primary outcome occurred in 105 patients (1\uc2\ub75 per 100 person-years) who were given pioglitazone and 108 (1\uc2\ub75 per 100 person-years) who were given sulfonylureas (hazard ratio 0\uc2\ub796, 95% CI 0\uc2\ub774\ue2\u80\u931\uc2\ub726, p=0\uc2\ub779). Fewer patients had hypoglycaemias in the pioglitazone group than in the sulfonylureas group (148 [10%] vs 508 [34%], p<0\uc2\ub70001). Moderate weight gain (less than 2 kg, on average) occurred in both groups. Rates of heart failure, bladder cancer, and fractures were not significantly different between treatment groups. Interpretation In this long-term, pragmatic trial, incidence of cardiovascular events was similar with sulfonylureas (mostly glimepiride and gliclazide) and pioglitazone as add-on treatments to metformin. Both of these widely available and affordable treatments are suitable options with respect to efficacy and adverse events, although pioglitazone was associated with fewer hypoglycaemia events. Funding Italian Medicines Agency, Diabete Ricerca, and Italian Diabetes Society